Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Closes First Part of Financing Round

NEW YORK (GenomeWeb) – Protagen said today that it has closed the first part of a financing round that targets €10 million ($12.5 million).

The German firm did not disclose the amount raised in the first close. It added that it plans a second closing in the third quarter of 2015 with additional new investors.

Qiagen participated in the first close, joining existing investors MIG Fonds, NRW.Bank, and Protagen management. Qiagen and Protagen last month announced a long-term collaboration on research into protein-based companion diagnostics for autoimmune disorders. 

Protagen CEO Stefan Müllner said in a statement that it will use the funds to complete and commercialize in vitro diagnostic tests for rheumatoid arthritis, systemic lupus, and systemic sclerosis.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.